| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Pediatrics,
Department of Internal Medicine, and
Department of Surgery, Virginia Commonwealth University, Richmond, VA 23298
The current study characterizes the cytokine protein (ELISA) and mRNA (gene array and RT-PCR) profiles of skin-derived mast cells cultured under serum-free conditions when activated by cross-linking of Fc
RI. Prior to mast cell activation, mRNA only for TNF-
was detected, while after activation mRNA for IL-5, IL-6, IL-13, TNF-, and GM-CSF substantially increased, and for IL-4 it minimally increased. However, at the protein level certain recombinant cytokines, as measured by ELISAs, were degraded by proteases released by these skin-derived mast cells. IL-6 and IL-13 were most susceptible, followed by IL-5 and TNF-; GM-CSF was completely resistant. These observations also held for the endogenous cytokines produced by activated mast cells. By using protease inhibitors, chymase and cathepsin G, not tryptase, were identified in the mast cell releasates as the likely culprits that digest these cytokines. Their cytokine-degrading capabilities were confirmed with purified chymase and cathepsin G. Soy bean trypsin inhibitor, when added to mast cell releasates, prevented the degradation of exogenously added cytokines and, when added to mast cells prior to their activation, prevented degradation of susceptible endogenous cytokines without affecting either degranulation or GM-CSF production. Consequently, substantial levels of IL-5, IL-6, IL-13, TNF-, and GM-CSF were detected 24–48 h after mast cells had been activated, while none were detected 15 min after activation, by which time preformed granule mediators had been released. IL-4 was not detected at any time point. Thus, unless cytokines are protected from degradation by endogenous proteases, cytokine production by human mast cells with chymase and cathepsin G cells may be grossly underestimated.
This article has been cited by other articles:
|
|
 |
|
  R. E. Sutherland, J. S. Olsen, A. McKinstry, S. A. Villalta, and P. J. Wolters Mast Cell IL-6 Improves Survival from Klebsiella Pneumonia and Sepsis by Enhancing Neutrophil Killing J. Immunol., October 15, 2008; 181(8): 5598 - 5605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Tiwari, C.-C. Wang, C. Brochetta, G. Ke, F. Vita, Z. Qi, J. Rivera, M. R. Soranzo, G. Zabucchi, W. Hong, et al. VAMP-8 segregates mast cell-preformed mediator exocytosis from cytokine trafficking pathways Blood, April 1, 2008; 111(7): 3665 - 3674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Gomez, S. Jogie-Brahim, M. Shima, and L. B. Schwartz Omalizumab Reverses the Phenotypic and Functional Effects of IgE-Enhanced Fc{epsilon}RI on Human Skin Mast Cells J. Immunol., July 15, 2007; 179(2): 1353 - 1361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Roosterman, T. Goerge, S. W. Schneider, N. W. Bunnett, and M. Steinhoff Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. Physiol Rev, October 1, 2006; 86(4): 1309 - 1379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Zhao, C. L. Kepley, P. A. Morel, L. M. Okumoto, Y. Fukuoka, and L. B. Schwartz Fc{gamma}RIIa, Not Fc{gamma}RIIb, Is Constitutively and Functionally Expressed on Skin-Derived Human Mast Cells J. Immunol., July 1, 2006; 177(1): 694 - 701. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q.-Y. Zhang, J.-B. Ge, J.-Z. Chen, J.-H. Zhu, L.-H. Zhang, C.-P. Lau, and H.-F. Tse Mast Cell Contributes to Cardiomyocyte Apoptosis after Coronary Microembolization J. Histochem. Cytochem., May 1, 2006; 54(5): 515 - 523. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
